vs
AbCellera Biologics Inc.（ABCL）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
AbCellera Biologics Inc.的季度营收约是万物新生的1.0倍（$44.9M vs $43.2M），万物新生净利率更高（16.9% vs -19.9%，领先36.8%）
AbCellera Biologics是一家总部位于不列颠哥伦比亚省温哥华的生物科技企业，核心业务是探索与开发抗体治疗药物。该公司凭借 proprietary 技术平台可在60天内开发出医疗应对方案，其单细胞筛选技术平台最早诞生于不列颠哥伦比亚大学，还曾作为核心力量参与美国国防高级研究计划局的大流行预防平台项目。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
ABCL vs RERE — 直观对比
营收规模更大
ABCL
是对方的1.0倍
$43.2M
净利率更高
RERE
高出36.8%
-19.9%
损益表 — Q4 FY2025 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $44.9M | $43.2M |
| 净利润 | $-8.9M | $7.3M |
| 毛利率 | — | — |
| 营业利润率 | -63.7% | — |
| 净利率 | -19.9% | 16.9% |
| 营收同比 | 788.4% | — |
| 净利润同比 | 73.9% | — |
| 每股收益（稀释后） | $-0.03 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABCLRERE
| Q4 25 | $44.9M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $17.1M | — | ||
| Q1 25 | $4.2M | — | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $10.0M | — |
净利润ABCLRERE
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | — | ||
| Q2 25 | $-34.7M | — | ||
| Q1 25 | $-45.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | — | ||
| Q2 24 | $-36.9M | — | ||
| Q1 24 | $-40.6M | — |
营业利润率ABCLRERE
| Q4 25 | -63.7% | — | ||
| Q3 25 | -851.8% | — | ||
| Q2 25 | -290.2% | — | ||
| Q1 25 | -1479.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1439.4% | — | ||
| Q2 24 | -1276.2% | — | ||
| Q1 24 | -551.5% | — |
净利率ABCLRERE
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | — | ||
| Q2 25 | -203.3% | — | ||
| Q1 25 | -1077.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | — | ||
| Q2 24 | -504.3% | — | ||
| Q1 24 | -408.0% | — |
每股收益（稀释后）ABCLRERE
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.19 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.14 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $128.5M | $228.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $966.9M | $557.1M |
| 总资产 | $1.4B | $722.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABCLRERE
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | — | ||
| Q2 25 | $92.4M | — | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | — | ||
| Q2 24 | $148.3M | — | ||
| Q1 24 | $123.6M | — |
股东权益ABCLRERE
| Q4 25 | $966.9M | — | ||
| Q3 25 | $964.0M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
总资产ABCLRERE
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.5B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-34.7M | — |
| 自由现金流经营现金流 - 资本支出 | $-44.6M | — |
| 自由现金流率自由现金流/营收 | -99.4% | — |
| 资本支出强度资本支出/营收 | 21.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-174.1M | — |
8季度趋势，按日历期对齐
经营现金流ABCLRERE
| Q4 25 | $-34.7M | — | ||
| Q3 25 | $-52.6M | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-11.6M | — | ||
| Q4 24 | $-108.6M | — | ||
| Q3 24 | $-28.9M | — | ||
| Q2 24 | $-30.0M | — | ||
| Q1 24 | $-41.7M | — |
自由现金流ABCLRERE
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | — | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — | ||
| Q1 24 | $-65.8M | — |
自由现金流率ABCLRERE
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | — | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — | ||
| Q1 24 | -661.5% | — |
资本支出强度ABCLRERE
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | — | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — | ||
| Q1 24 | 242.5% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
